AstraZeneca and Conformetrix have signed a research collaboration agreement applying Conformetrix’s proprietary NMR-based technology across AZ’s preclinical therapeutic pipeline. Under the terms of the two-year collaboration, the technology will also be used to determine the bioactive conformations of naturally occurring ligands as templates for drug library enhancement and hit identification. Financial terms were not disclosed, but in addition to an undisclosed upfront payment, Conf...